Ronen Arbel, Enis Aboalhasan, Ariel Hammerman, Joseph Azuri, Usefulness of Sodium-Glucose Cotransporter 2 Inhibitors for Primary Prevention of Heart Failure in Patients With Type 2 Diabetes Mellitus,
The American Journal of Cardiology, Volume 150, 2021, Pages 65-68

Ronen Arbel, Enis Aboalhasan, Ariel Hammerman, Joseph Azuri, Icosapent Ethyl for Primary Versus Secondary Prevention of Major Adverse Cardiovascular Events in Hypertriglyceridemia: Value for Money Analysis, The American Journal of Medicine, Volume 134, Issue 7, 2021, Pages e415-e419

Ronen Arbel, Enis Aboalhasan, Ariel Hammerman, Joseph Azuri, Dapagliflozin vs. sacubitril-valsartan for prevention of heart failure events in non-diabetic patients with reduced ejection fraction: a cost per outcome analysis, European Journal of Preventive Cardiology, 2020;, zwaa136,

Arbel, R., Aboalhasan, E., Hammerman, A. et al. Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Heart Failure Events in Patients with Type 2 Diabetes Mellitus: A Cost Per Outcome Analysis. Clin Drug Investig 40, 665–669 (2020).

Arbel, R., Sergienko R., Hammerman, A., Greenberg-Dotan, S, Batat E., Avnery O., Greenberg, D. & Ellis, MH. (2019) Direct anticoagulation and mortality in atrial fibrillation. Heart 105(19):1487-1492.(IF: 5.1; Ranked Q1 in Cardiology).

Arbel, R., Sergienko R., Hammerman, A., Greenberg-Dotan, S, Batat E., Avnery O., & Ellis, MH. (2019). Effectiveness and Safety of Off-Label Dose-Reduced Direct Oral Anticoagulants in Atrial Fibrillation. American Journal of Medicine 132(7):847-855. (IF: 5.1; Ranked Q1 in Medicine)

Arbel, R., Hammerman, A., & Azuri, J. (2018). Usefulness of Ezetimibe Versus Evolocumab as Add-on Therapy for Secondary Prevention of Cardiovascular Events in Patients with Type 2 Diabetes Mellitus. American Journal of Cardiology 123 (8), 1273-1276. (Impact Factor: 3.2; Ranked Q1 in Cardiology)

Arbel, R., Hammerman, A., & Azuri, J. (2018). Usefulness of empagliflozin versus liraglutide for prevention of cardiovascular mortality. American Journal of Cardiology 122, 981-984. (Impact Factor: 3.2; Ranked Q1 in Cardiology)

Arbel, R. & Greenberg, D. (2017). Using lower-cost statins improves outcomes for normal cholesterol non-diabetic patients. Expert Review of Pharmacoeconomics & Outcomes Research. 17, 495-501. (Impact Factor: 1.8; Ranked Q2 in health policy)

Arbel, R. & Greenberg, D. (2016). Rethinking cost-effectiveness in the era of zero healthcare spending growth. International Journal for Equity in Health, 15, 1-7. (5-year Impact factor: 2.4; ranked Q1 in Health Policy)

Arbel, R., Hammerman A., Triki N. & Greenberg, D. (2016) PCSK9 inhibitors may improve cardiovascular outcomes—can we afford them? International Journal of Cardiology, 220, 242–245. (Impact Factor: 4.0; ranked Q1 in Cardiology)